Abstract: Introduction: Hyperthermic IntraPeritoneal Chemotherapy (HIPEC) has evolved as a treatment for peritoneal carcinomatosis in various tumors after a careful and complete cytoreductive surgery, and it demonstrated much better and longer survival than more traditional therapeutic schemas. Our objective has been to examine the safety, efficacy and survival achieved with closed technique with CO2-agitation system Combat PRS® (Peritoneal Recirculation System: PRS). To achieve this, we compared the appearance of adverse events, mortality and survival with the described using classic techniques (open, closed without CO2-agitation) for the treatment of selected patients with peritoneal carcinomatosis; Materials and methods: We studied overall survival, disease-free survival and safety (morbidity and mortality) of the administration of HIPEC through a closed method technique with CO2 recirculation (Combat PRS®) in 482 patients from 11 Spanish hospitals; Results: The mortality of our technique (1.66%) was similar to other published techniques (open, closed). Morbidity exhibited a 9.96% rate of Clavien-Dindo (CD) III/IV complications in 482 patients, which was lower than in other series. Survival (overall survival (OS) and disease-free survival (DFS)) was similar to previously published results: 86% 1y-OS, 54% 3y-OS, 77% 1y-DFS and 31% 3y-DFS; Conclusion: The procedure with closed PRS with CO2 agitation is as safe as standard open and closed procedures for the administration of HIPEC after complete cytoreductive surgery, with similar and very low mortality (1.66%) and lower morbidity (9.96% CD III and IV in our series vs range of 20–40% in the majority of different series); only Kusamura had similar results, with 12% in 205 patients, using combat PRS®-agitation. The combination of cytoreductive surgery and perioperative chemotherapy [1–7] is the treatment of choice for select patients with peritoneal carcinomatosis of many tumors (e.g., peritoneal pseudomyxoma, mesothelioma or colon tumors [8–10]), and it has great promise in other tumor types [11] (e.g., gastric [12–15] or ovarian origin [1,2,16]).

1. Introduction

The combination of cytoreductive surgery and perioperative chemotherapy [1–7] is the treatment of choice for select patients with peritoneal carcinomatosis of many tumors (e.g., peritoneal pseudomyxoma, mesothelioma or colon tumors [8–10]), and it has great promise in other tumor types [11] (e.g., gastric [12–15] or ovarian origin [1,2,16]).
Cytoreductive surgery (CRS) aims to completely remove all macroscopically visible tumors, and perioperative chemotherapy (CT) acts in a complementarily way to eradicate microscopic residual implants [4–6]. Although cytoreductive surgery procedures have become quite standardized since the publication of peritonectomy techniques by Sugarbaker, this standardization has not occurred with intraperitoneal chemotherapy, which has many existing protocols involving different chemotherapeutic drugs, durations, temperatures and application methods. [17].

CRS with intraoperative chemotherapy are usually long and complex procedures, usually involving multivisceral and peritoneal resections, with great systemic surgical repercussion and the added toxicity of concomitant, intraoperative and chemotherapy, but the long-term results are encouraging [4,18,19].

The HIPEC rationale is deliver a higher dosage of chemotherapy on the locoregional extension of the tumor (the peritoneal surface) with lower systemic toxicity. The direct introduction of chemotherapy in the peritoneal cavity achieves this objective, but this is further improved by hyperthermia, which enhances the penetration depth of cytotoxic drugs. This depth is limited and, therefore, can be only effective in patients with minimal residual disease after complete CRS [20].

The drugs, methods of application and timing of chemotherapy, however differ between work groups, and new techniques and methods have evolved to optimize the application of chemotherapeutic agents. Although HIPEC is the most widely used procedure in leading oncological centers, it lacks uniformity [2,6,21], with extensive variability in chemotherapeutic drugs, chemotherapeutic contact durations and methods of administration. Open, closed, half-open techniques or treatment with peritoneal cavity expansion coexist with the most recent contributions of a laparoscopic method (PIPAC) and closed technique with CO₂ agitation (Combat PRS®). The best technique remains controversial [22].

Theoretical advantages of a closed system with CO₂ agitation (Combat PRS®) are to maintain a more constant temperature within the peritoneal cavity, to achieve a homogeneous distribution of the chemotherapy selected and diminish the risk for operating system, as its assembly is easy and staff have minimal contact with chemotherapy (only during final aspiration of the abdominal cavity); this has been tested in pigs [23]).

Our objective is to examine whether the closed technique with the CO₂-agitation system (Combat PRS®) was a safe and effective treatment of select patients with peritoneal carcinomatosis in real world practice, in 11 hospitals in Spain.

2. Materials and Methods

This study was a multi-center, retrospective study of 11 Spanish hospitals (Table 1, Figure 1a–d) that used the closed technique with CO₂ agitation (Combat PRS®, Madrid, Spain) in the context of the multidisciplinary treatment of peritoneal carcinomatosis.

Table 1. Participating hospitals, patients provided (yearly tumoral histology) and evolution over time of the number of procedures. (Pseud: pseudomyxoma. Perit: primary peritoneal. Mesot: peritoneal mesothelioma. Sarco: peritoneal sarcoma. Append: appendix. Panc: pancreas).

| Series | Colon | Ovarian | Gastric | Pseud. | Perit. | Mesot. | Sarco. | Append. | Panc. | Other | Total |
|--------|-------|---------|---------|--------|--------|--------|--------|---------|-------|-------|-------|
| 2011   | 3     |         |         |        |        |        |        |         |       |       | 3     |
| 2012   | 10    |         |         |        |        |        |        |         |       |       | 10    |
| 2013   | 5     | 14      | 1       |        |        |        |        |         |       |       | 20    |
| 2014   | 15    | 8       | 9       |        |        |        |        |         |       |       | 35    |
| 2015   | 28    | 14      | 10      | 2      | 1      | 1      | 4      |         |       |       | 60    |
| 2016   | 28    | 25      | 9       | 4      | 1      | 3      |        |         |       |       | 71    |
| 2017   | 55    | 20      | 8       | 11     | 1      | 2      | 5      | 1       | 1     | 1     | 104   |
| 2018   | 70    | 46      | 11      | 14     | 1      | 2      | 1      | 6       | 2     | 1     | 153   |
| 2019   | 9     | 9       | 1       | 1      |        |        | 2      | 1       | 2     | 1     | 26    |
### Table 1. Cont.

| Series                  | Colon | Ovarian | Gastric | Pseud. | Perit. | Mesot. | Sarco. | Append. | Panc. | Other | Total |
|-------------------------|-------|---------|---------|--------|--------|--------|--------|---------|-------|-------|-------|
| Total                   | 210   | 149     | 49      | 32     | 2      | 10     | 2      | 14      | 9     | 5     | 482   |
| Cumulative Series 2019  |       |         |         |        |        |        |        |         |       |       |       |
| Fuenlabrada University Hospital | 101   |         |         |        |        |        |        |         |       |       |       |
| Cuidad Real University Hospital | 79    |         |         |        |        |        |        |         |       |       |       |
| Principe de Asturias University Hospital | 85    |         |         |        |        |        |        |         |       |       |       |
| Gran Canaria Insular Hospital | 71    |         |         |        |        |        |        |         |       |       |       |
| Madrid Sanchinarro University Hospital | 47    |         |         |        |        |        |        |         |       |       |       |
| University of Malaga Regional University Hospital | 45    |         |         |        |        |        |        |         |       |       |       |
| Fundación Alcorcon University Hospital | 18    |         |         |        |        |        |        |         |       |       |       |
| Elche General University Hospital | 14    |         |         |        |        |        |        |         |       |       |       |
| Reina Sofia University Hospital | 14    |         |         |        |        |        |        |         |       |       |       |
| FJD University Hospital | 2     |         |         |        |        |        |        |         |       |       |       |
| Virgen de Arraixaca University Hospital | 6     |         |         |        |        |        |        |         |       |       |       |
| TOTAL                   | 482   |         |         |        |        |        |        |         |       |       |       |

*Figure 1. Cont.*
Figure 1. (a) Eleven participating hospitals. (b) Yearly increase of total HIPEC procedures. (c) Yearly increase of HIPEC procedures, with area proportional to histology, showing that the two main histologies are colon and ovarian origin. (d) Yearly evolution of HIPEC procedures with disaggregated yearly histology.

The study period was from 2011 to February 2019, with a gradual and strong increase in the number of patients treated using this technique during this period (Table 2, Figure 2a,b).

Table 2. Types of tumours.

| Tumour          | Total | %    | Clinical PCI       | Surgery PCI        |
|-----------------|-------|------|--------------------|--------------------|
| Colon           | 210   | 43.6 | 4.6 (3.89–5.31)    | 6.37 (5.44–7.30)   |
| Ovarian         | 149   | 30.9 | 8.58 (7.47–9.70)   | 9.68 (8.49–10.88)  |
| Gastric         | 49    | 10.2 | 4.04 (2.12–5.96)   | 4.89 (2.81–6.98)   |
| Appendix        | 14    | 2.9  | 8.64 (7.54–9.30)   | 10.33 (9.25–11.10) |
| Pseudomixoma    | 32    | 6.6  | 8.59 (7.20–9.70)   | 11.78 (10.50–12.36)|
| Mesothelioma    | 10    | 2.1  | 19.63 (17.25–20.50)| 21.78 (18.30–22.45)|
| Pancreas        | 9     | 1.9  |                    |                    |
| Other           | 4     | 0.8  |                    |                    |
| Primary peritoneal | 2   | 0.4  |                    |                    |
| Endometrium     | 1     | 0.2  |                    |                    |
| Sarcoma         | 2     | 0.4  |                    |                    |
| **Total**       | 482   | 100% |                    |                    |
Figure 2. (a) Histology: yearly evolution of HIPEC procedures. (b) Total HIPEC procedures by histology.

The study included 482 patients who met the specific inclusion criteria (Table 3). All patients received HIPEC with a CO₂-agitation system and the same perfusion machine (Combat PRS®). The surgical approach in every case was the one described by Sugarbaker [17]. The chemotherapeutics used and the treatment time varied according to the preferred protocol of each participating center.

Table 3. Inclusion criteria [24].

- Complete Cytoreduction (R0 resective surgery)
- Age < 75 years
- Functional Status According to WHO (ECOG) ≤ 2
- Presence of Peritoneal Carcinomatosis
- Absence of Extra-Abdominal Metastasis
- Absence of Hepatic Metastasis requiring a major or nonresectable hepatectomy
- Liver, Kidney and Bone Marrow function within these parameters:
  - Total Bilirubin ≤ 1.5 times the upper limit of normal (ULN)
  - GOT/GPT ≤ 2.5 times ULN
  - AP ≤ 3 times ULN
  - Serum Creatinine ≤ 1.5 times NFS
  - Neutrophils > 1.5 × 10³
  - Hb > 10 g/dL
  - Platelets > 100,000
Twenty-four variables were collected in a prospective database created for this purpose. The carcinomatosis index was quantified according to the peritoneal cancer index (PCI) described by Sugarbaker [25–27]. Data were collected on intraoperative complications related to the surgery, and data linked to HIPEC were collected separately. Complications detected in the postoperative period were recorded and codified according to the 2004 version of the Clavien-Dindo (CD) scale [28]. (Clavien-Dindo I and II are deviations from normal postoperative course solved pharmacologically; CD III are complications which require surgical/endooscopic or radiologic intervention without (IIIa) or with (IIIb) general anesthesia, and CD IV are life-threatening complications that require admission to Intensive Care Unit (ICU), with single organ (IVa) or multiorgan (IVb) disfunction. CD V is death: “mortality”). For the analysis of morbidity, CD III and IV have been taken into account (as reported in the main articles of Table 4).

| Authors et al. [29] | Open | 356 | 2006 | AP | 2 | 19 | - | - | IV (proprietary base) |
|---------------------|------|-----|------|----|---|----|---|---|----------------------|
| Elias et al. [30]   | Open Closed | 523 | 2010 | CRC | 3.3 | 31 | 1 y: 81%, 3 y: 41%, 5 y: 27% | 1 y: 47%, 3 y: 15%, 5 y: 10% | CD: III/IV |
| Goire [11] (PSOGI)  | Open Closed | 781 | 2017 | Rare OC, Sarcomas, NT | 2.9 | 41 | 1 y: 78%, 3 y: 52%, 5 y: 39% | 1 y: 61%, 3 y: 33%, 5 y: 28% | CTCAE 4 |
| Glehen et al. [31]  | Closed | 207 | 2003 | OC, CRC, GC, PMP, PM, others | 3.2 | 24.5 | - | - | CD: III/IV |
| Kusamura et al. [32] | Closed | 205 | 2006 | OC, CRC, GC, PMP, PM, others | 0.9 | 12 | - | - | Bozzetti: 3–4 |
| Levine et al. [33]  | Closed | 460 | 2007 | OC, CRC, GC, PMP, PM, PS, others | 4.8 | 43 | 3 y: 60% | - | Not described |
| Manzanedo et al. [15] (GECOP) | Open Closed PRS | 242 | 2019 | GC | 3.4 | 31 | 1 y: 80%, 3 y: 31% | 1 y: 46%, 3 y: 22% | CD (v2004): III/IV |
| Sanchez-Garcia et al. [34] | Closed PRS | 88 | 2016 | OC | 4.76 | 38.1 | - | - | CD: III/IV |
| Cianci [35]         | Closed PRS | 17 | 2018 | CRC, OC, AP, GC | 0 | 38.1 | - | - | CD: III/IV |

GC: gastric cancer. CRC: colorectal cancer. AP: appendiceal cancer. OC: ovarian cancer. PMP: pseudomyxoma peritoneal mesothelioma. NT: neuroendocrine tumor. CTCAE: Common Terminology Criteria for Adverse Events. CD: Clavien-Dindo. GECOP: Spanish group of peritoneal oncologic surgery. Note: “Mortality” equals Clavien-Dindo V. 1 y: 1 year. 3 y: 3 year. 5 y: 5 year.

IBM-SPSS, version 22 (IBM, Armonk, NY, USA), was used for statistical analyses. Actual survival was calculated using Kaplan–Meier curves.

**Description of HIPEC Administration Technique**

The closed technique with CO₂ agitation is based on the existence of two closed circuits. One circuit is filled with chemotherapy agents, and the other circuit is filled with gas bubbles (CO₂).

After complete cytoreduction and exposure of all appropriate abdominal cavities, the base of the control device was passed through a small orifice (2 cm) in the abdominal wall.
to connect the cavity to a transparent extracorporeal cylinder (Figure 3a,b) that allowed us to monitor the proper level of filling and the intraabdominal pressure (which was approximately equal to the height of the water column over the skin level within this control device). This device was held in a vertical and stable position by an external arm tightly attached to the operating table. The three thinner multiperforated tubes for gas intake (Figure 3a (light green)) were positioned under the intestinal package and extended like a trident at the root of the mesentery. All tubes converged into a single tube, which exited the cavity through another small (1 cm) skin orifice over the left iliac fossa. This tube may be used to place a drain at the end of the procedure. A recirculation circuit of CO₂ was established between these tubes (gas inlet) and the upper part of the control device (gas outlet (Figure 3a (black dot)).

Chemotherapeutic drugs in a liquid carrier solution were administered (inflow) via specially designed, multiperforated Y-shaped tubes with blunt ends (Figure 3a (white)), which were exteriorized through the lower part of the laparotomy and placed superficially over the visceral package. After entering the abdominal cavity, the solution was recovered (outflow) and recirculated through similar tubes with a larger diameter than the gas tubes (Figure 3a (blue)), which were exteriorized through the upper end of the laparotomy and positioned deeply in both parietocolic gutters. Once the tubes were placed, the laparotomy was closed as tightly as possible using continuous blocking stitches in the skin to allow impregnation of the abdominal wall with the chemotherapeutic agents during recirculation. After skin closure, recirculation of the solvent/carrier solution (transport liquid without chemotherapy) was started to test patency without external contamination risk. The solvent was generally the same liquid used for peritoneal dialysis (Physioneal 35, with 1.36% glucose) and preheated to 42 °C. After verification of correct recirculation, the gas was introduced to test the gas circuit. Once the desired amount of CO₂ had been introduced, it only recirculated within its own circuit. Chemotherapeutic agents were added after confirmation that both circuits were functioning properly. Recirculation of CO₂ aims to cause a turbulent flow that ensures a homogenous mixture of the chemotherapeutic agent solution and heat throughout the entire abdominal cavity.

Figure 3. HIPEC and HITAC schematic view. Part (a) schematic view of the HIPEC system (white IN-blue OUT for chemotherapy, light green IN-dark green OUT for CO₂; in pink, the HITAC modification, allowing chemotherapy recover from pleural cavities. Part (b) real intraoperative setting of HIPEC with Combat PRS® (Author: E. Ovejero-Merino).
The dose of chemotherapy was calculated according to the surface area of the patient’s body, and the amount of transport fluid depended on the capacity of each patient’s abdominal cavity, tissue compliance and degree of anaesthetic relaxation.

After completion of the recirculation time, the cavity was drained via the outlet tubes. Two full 5-min washes were performed with a clean, gas-free recirculation liquid to remove any remnant chemotherapeutic agents. After the last wash, the abdominal cavity was reopened, and any remaining liquid was manually suctioned. All disposable material was removed from the patient and directly placed into biological waste buckets to minimize the risk of contamination of operating room staff.

The diagram presents the variation used when it was necessary to open or resect any part of the diaphragm, which allowed cells to potentially reach the pleural cavity. This variation allowed perfusion and recovery of the recirculation fluid from the pleural cavity during the perfusion by connecting chest tubes to the outlet tubes. This variation was named HIperthermic ThoracoAbdominal Chemotherapy (HITAC).

3. Results

3.1. Description of the Series

Of the 482 patients, 66.4% were women and 33.6% were men. The average age at the time of the surgery was 59 years (CI ± 11.39).

In total, 210 cases were colon tumors, 149 cases were ovarian tumors, 49 cases were gastric tumors, 32 cases were pseudomyxoma, 14 cases were appendicular tumors, 10 cases were mesothelioma, 2 cases were primary peritoneal tumors and 16 cases were other tumors (i.e., 9 pancreas, 1 endometrial, 2 sarcomas, 1 neuroendocrine and 3 GIST) (Table 2).

The global mean hospital stay was 13.4 days with 3.2 days in the ICU. There were no significant differences related to the type of tumor.

For the procedures performed in the cytoreduction, more than four procedures were performed in 215 patients (44.6%).

3.2. Peritoneal Carcinomatosis Index (PCI)

The clinical PCI was lower than the PCI during surgery in all the included tumors (Table 2).

3.3. Chemotherapeutic Drugs

For colon tumors, the most commonly used agents were mitomycin C for 60 to 90 min (46.2%) and oxaliplatin for 30 min (45.7%).

The preferred drugs for ovarian tumors were paclitaxel (61.7%) and the combination cisplatin/doxorubicin (16.1%) for 60 min.

For gastric carcinomatosis, the most frequent combination (42.9%) was cisplatin and mitomycin C for 60 min.

For pseudomyxoma tumors, mitomycin C for 60 min was used in 78.1% of the cases.

For mesothelioma tumors, most cases (66.6%) received the combination cisplatin and doxorubicin for 90 min.

3.4. Morbidity/Mortality

A total of 170 patients (35.27%) exhibited complications during their hospital stay, and we classified the adverse events using the Clavien-Dindo scale. Only 48 of these adverse events (9.96%) were serious (CD III/IV) (Table 5).
Table 5. Part (a) Relation between variables and increased morbidity; Part (b) Postoperative deaths (Clavien-Dindo V) (Decade 1 = 0–9 years; decade 2 = 10–19 years, and so on); Part (c) HIPEC specifically-related complications (CD II).

(a) Complications CD III/IV

| Complications | Statistic | p Value | Risk | CI       |
|---------------|-----------|---------|------|---------|
| >4 procedures | Chi squared | 0.035   | 1.928 | (1.16–3.20) |
| Surgical PCI  | Mann–Whitney U | 0.154   |       |         |
| Age           | Mann–Whitney U | 0.888   |       |         |
| Type of primary tumour | Chi squared | 0.387   |       |         |
| Medicine      | Chi squared | 0.103   |       |         |
| Sex           | Chi squared | 0.088   |       |         |
| HIPEC time    | Mann–Whitney U | 0.793   |       |         |

(b) Case ID Age (Decade) Histology Postop Day HIPEC Drugs HIPEC Time ICU Days Cause of Death

| Case ID | Age (Decade) | Histology | Postop Day | HIPEC Drugs | HIPEC Time | ICU Days | Cause of Death               |
|---------|--------------|-----------|------------|--------------|------------|----------|-------------------------------|
| HUCR11  | 7 th         | Ovarian   | 8          | Paclitaxel   | 60         | 7        | Probable PE, CRA              |
|         |              |           |            |              |            |          | Intestinal perforation        |
|         |              |           |            |              |            |          | Peritonitis                   |
|         |              |           |            |              |            |          | Multi-organ failure           |
|         |              |           |            |              |            |          | Intestinal bleeding           |
|         |              |           |            |              |            |          | Multi-organ failure           |
| HUCR35  | 8 th         | Ovarian   | 12         | Paclitaxel   | 60         | 8        | Sepsis                        |
|         |              |           |            |              |            |          | MI                            |
| HUCR36  | 7 th         | Ovarian   | 3          | Paclitaxel   | 60         | 17       | Sepsis                        |
|         |              |           |            |              |            |          | MI                            |
| HMS12   | 5 th         | Colon     | 17         | Oxaliplatin  | 60         | 79       | Intestinal perforation        |
|         |              |           |            |              |            |          | Peritonitis                   |
|         |              |           |            |              |            |          | Multi-organ failure           |
| HUPA70  | 6 th         | Pseudomyxoma | 35       | Mitomycin C + 5FU + Folinic | 90 | 3 | PE |
|         |              |           |            |              |            |          | Post-operative LGIB           |
| HRUM18  | 8 th         | Colon     | 3          | Oxaliplatin  | 30         | 8        | Fatal and unexpected liver failure |
| HRUM18  | 7 th         | Ovary     | 3          | Oxyplatin    | 30         | 8        | Pericardial bleed              |
| HRUM21  | 5 th         | Ovary     | 2          | Oxaliplatin  | 3          | 3        | Hyperglycaemia                |
|         |              |           |            |              |            |          | Metabolic acidosis            |
| HRUM22  | 7 th         | Colon     | 6          | Oxaliplatin  | 3          | 3        | Hyperglycaemia                |
|         |              |           |            |              |            |          | Metabolic acidosis            |
| HRUM30  | 6 th         | Colon     | 4          | Mitomycin    | 30         | 60       | Hyperglycaemia                |
|         |              |           |            |              |            |          | Metabolic acidosis            |
| HRUM40  | 6 th         | Colon     | 4          | Oxaliplatin  | 30         | 3        | Hyperglycaemia                |
|         |              |           |            |              |            |          | Metabolic acidosis            |
| HGUE    | 5 th         | Ovary     | Yes        | Paclitaxel   | 13         | 13       | Hypercarbia                   |

Variables, such as age, drug used, PCI, type of primary tumor or HIPEC time, were not associated with increased morbidity. Only the number of procedures > 4 was significantly linked to an increase in morbidity.

Eight patients died in the postoperative period (1.66%). Four deaths were due to medical causes (PE, MI and liver failure), and the other deaths were due to causes directly related to the surgery (intestinal perforation, sepsis and lower GI bleeding). None of these deaths were directly related to the administration of HIPEC.

We found nine cases with complications that were linked exclusively to HIPEC (detected during the procedure) (1.9% of the total): six hyperglycaemia cases over 400 mg/dL, one allergy to oxaliplatin (anaphylactic shock), one significant metabolic acidosis and one case of hypercarbia (the only directly relatable with CO₂ agitation). Seven cases were colon carcinomatosis (two appendiceal), and two cases were ovarian. The HIPEC duration was
30 min in 5 of the nine cases. The complications linked to HIPEC did not significantly increase the stay in the ICU.

Hyperglycaemia >400 mg/dL was related to carrier solution (5% dextrose) and was avoided, and in further procedures, carrier solution was switched to peritoneal dialysis fluid (Physioneal 35, with 1.36% glucose). With no known clinical significance of the difference, 5% dextrose maintains a concentration of oxaliplatin at levels that reach 101.2% at 60′ and 105.1% at 120′ of HIPEC, while peritoneal dialysis fluid levels slowly decrease to 91.7% at 60′ and 85.3% at 120′ of the original dosage, but avoids the serious hyperglycaemia and electrolyte disturbances caused by the former (5% dextrose). [36].

3.5. Survival Curves

The OS of the series with a mean follow-up of 17.8 months was 86.1% and 54.1% after the first and third years, with DFS rates of 77.2% and 31.4%, respectively; a direct comparison with the main series can be seen in Tables 4 and 6 and Figure 4. The data by tumoral histology are detailed in Figure 2.

![Figure 4](image-url)

**Figure 4.** Survival curves by histology. (a) DFS: disease-free survival; ovarian (pink), global group (red), pseudomyxoma (orange) appendix (blue), colon (brown), gastric (green). (b) GS: global survival; ovarian (pink), pseudomyxoma (yellow), global group (red), colon (brown), gastric (green).
Table 6. OS and DFS, by tumour histology, 1 and 3 years after HIPEC procedure.

| Tumour Origin       | Mean Follow-Up (Months) | OS 1 Year (%) | OS 3 Years (%) | DFS 1 Year (%) | DFS 3 Years (%) |
|---------------------|-------------------------|---------------|----------------|----------------|-----------------|
| Colon carcinomatosis| 17.7                    | 90.7%         | 48.7%          | 80.1%          | 23.4%           |
| Appendiceal carcinomatosis | 17.5         | 92.3%         | 64.6%          | 75.2%          | 51.6%           |
| Ovarian carcinomatosis | 18.8        | 89.1%         | 68.9%          | 80.8%          | 45.2%           |
| Gastric carcinomatosis | 17.3        | 65.8%         | 30.6%          | 63.5%          | 19.8%           |
| Pseudomyxoma        | 14          | 84.2%         | 52.6%          | 76.3%          | 33.9%           |
| Mesothelioma        | 16.2        | 50%           | 50%            | 50%            | 30%             |

4. Discussion

Cytoreductive surgery in the treatment of peritoneal carcinomatosis is a useful tool in centers with experience and appropriate patient selection [37] to increase overall and disease-free survival [38,39]. The rate of complications in these procedures, which sometimes require excision of the peritoneum and the resection of affected organs for the macroscopic elimination of the tumor, is very similar to other highly complex surgeries [38].

The role of intraperitoneal chemotherapy as a theoretical complementary treatment to surgery for the eradication of the residual microscopic tumor has not been completely demonstrated in prospective trials [40,41], which may be because it has a much less standardized protocol than surgery [42]. Therefore, each group uses different treatment protocols with different chemotherapeutic agents, times, temperatures and methods of application without any evidence of which protocol produces better results [39,43]. Therefore, it is difficult to obtain global and valid conclusions. Intraperitoneal chemotherapy is also used in other scenarios, such as the prophylaxis treatment of peritoneal carcinomatosis in high-risk tumors [44] or the treatment of malignant ascites [45].

Intraperitoneal chemotherapy acts directly on local tumor cells via various mechanisms. The chemotherapeutic drugs selected are generally hydrophiles, with high molecular-weight molecules to prevent the drugs from passing through the peritoneal barrier. This characteristic minimizes their passage into the bloodstream, decreases their systemic toxicity and achieves much higher intraperitoneal concentrations than would be possible or safe with systemic chemotherapy [46]. The selected agents must have a fast, direct cytotoxic effect on the residual tumor, which must not be larger than 2.5 mm because the chemotherapeutic agents will not completely permeate the full thickness of larger tumors during the recirculation time.

Hyperthermia theoretically acts in three ways [47–51]: the first mechanism produces a direct thermal cytotoxic effect on the tumor cell; the second mechanism increases the cytotoxicity of the chemotherapeutic agents; and the third mechanism increases the ability of the chemotherapeutic agent to penetrate inside tumoral implants. Hyperthermia itself seems to play a significant role in the efficacy of intraperitoneal chemotherapy, as Yonemura et al. founded: “HIPEC at 42–43 °C had better results than lower temperatures or no HIPEC (only CRS)” [52], but the ideal temperature in a varied range of chemotherapeutic agents still remains controversial, because not all chemotherapeutic drugs reach their maximum efficacy or stability at the same temperature [49]. Some recent publications related high temperatures (>41.4 °C) to lower survival rates [14], and other studies related these findings to the synthesis of heat shock proteins (HSP) inside tumor cells, which ultimately protected the tumor cells (“thermotolerance”) by reducing the apoptosis generated by the chemotherapeutic drugs or selecting the subpopulations of tumor cells that were most resistant to the administered chemotherapy [50]. HSP therapies are being investigated to prevent their protective actions and as a marker for cytotoxic drugs [47].

Therefore, the ideal temperature is not well defined and will likely vary depending on the drugs used when we have more knowledge of their behavior at high temperatures. However, we must be able to monitor the temperature of the chemotherapy very well, modify it and keep it constant and homogeneous within the cavity for maximum efficacy in all areas and to avoid heat damage in areas of possible accumulation.
Another significant influence on the efficacy of intraperitoneal chemotherapy is the intraabdominal pressure of the fluid. Increasing the intraabdominal pressure increases the penetration of the medicine into the cell layers of the tumor implant by collapsing the capillaries that wash the chemotherapeutic agents in the peritoneum and increases the concentration and permanence of the agent in contact with the tumoral cells [45, 53].

The most widely used method for the administration of perioperative chemotherapy is Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) [22, 54] because it unites the cytotoxic effect of chemotherapeutic agents with the effect of thermal shock on tumor cells. The classic method described by P. Sugarbaker is the open or “Coliseum” method, in which the chemotherapeutic agents are dissolved in a carrier solution, enter the abdominal cavity and are manually moved continuously to reach all areas of the peritoneum. However, the great difficulty of this method is maintaining a constant temperature throughout the entire abdomen. There are also safety concerns because of the direct and long-term contact of the surgeons with the chemotherapeutic drugs. A closed method was subsequently described to avoid possible exposure of the staff to the chemotherapeutic agents and maintain a more homogeneous temperature within the cavity and a higher intraabdominal pressure to help the penetration of chemotherapeutic agents into the tumor cells. The problem with this technique is the early formation of adhesions that hinder the ability to reach all areas of the peritoneum and the potential accumulation of heat or chemotherapeutic agents in some areas, which could lead to lesions or increased toxicity [22].

After several experimental trials in pigs [23] verified the safety of the technique, we started to use a new method for the administration of HIPEC in 2012, which was the closed technique with CO₂ recirculation (Combat PRS®, Madrid, Spain).

Regarding efficacy, our results are very promising, with a mean overall survival near 50% at 3 years in a pathology where the published survival without treatment is 6 months (49% in colon cancer, almost 70% in ovarian cancer and 30% for tumors when carcinomatosis appears as gastric cancer).

The grade III/IV morbidity of our series was 9.96%, which is within the expected range for a surgery of this complexity and consistent with other groups. The mortality was also within acceptable margins and was 1.66% in our series [40].

Various studies compared the classic open and closed methods, but no groups demonstrated that one procedure was better than the other. Therefore, the best application method of HIPEC remains controversial [1, 2].

In our experience, morbidity was lower by using the closed technique with CO₂ in comparison with previous literature [1–9]; thus, it seems to be a safe option. As the different studies used different systems to classify adverse events, a direct comparison using a metanalysis review is unfortunately not possible [28].

Based on the morbidity/mortality data of the entire process and the analysis of the complications directly related to HIPEC, we found that the severe adverse events were related either to the chemotherapeutic drug itself (anaphylactic shock) or the carrier medium (hyperglycemia). Only one case presented a plausibly related complication with CO₂ agitation, hypercarbia, and survived.

During the procedures, no accidents were documented for spillage or contamination of the operating room staff with the chemotherapeutic agents. One advantage for the Combat PRS® system is it is easy to mount and the cavity is closed and the gas is recirculated through the device, and thus the risk of inhaling any vapor created when heating the medicine is reduced to a minimum. Therefore, the procedure is also safe for health care staff when it is performed in compliance with the established protocol and security measures.

A main limitation of the study is the variability between centers because each center used a different treatment regimen with different chemotherapeutic drugs and times. These differences make it difficult for a comparison of concrete chemotherapy added or time of the technique. The variability in protocol as well as different length of follow-up in the included patients will require additional studies.
5. Conclusions

 According to the experience of our multi-center group, the closed system with CO₂ agitation seems to be a safe procedure for the application of HIPEC for the patient and health care staff. Only one patient suffered hypercarbia, which could be related directly to the CO₂ agitation use. This new protocol showed similar survival as the previously published series. The application of HIPEC with CO₂ recirculation using the Combat PRS® device, thus, seems to be a safe and effective procedure that may be added to the therapeutic arsenal in the multimodal treatment of peritoneal carcinomatosis.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm11206152/s1, Spanish PRS collaborating group: Dr. Israel Manzanedo, on behalf of the Department of General and Digestive Surgery, Hospital Universitario Fuenlabrada, Madrid, Spain. Dra. Susana Sánchez García, on behalf of the Department of General and Digestive Surgery, Hospital Universitario de Ciudad Real. Dra. Laura González Sánchez, on behalf of the Department of General and Digestive Surgery Hospital Insular de Gran Canaria. Dr. Eduardo Díaz Reques, on behalf of the Department of General and Digestive Surgery, Hospital Universitario Madrid Sanchinarro. Dr. Alberto Titos García, on behalf of the Department of General and Digestive Surgery, Hospital Regional Universitario de Málaga. Dr. Manuel E. Marcello Fernández, on behalf of Hospital Universitario Fundación Alcorcón, Madrid, Spain. Dr. Ibáñ Caravaca García, on behalf of Hospital General Universitario de Elche, Alicante, Spain. Dr. Álvaro Arjona, on behalf of the Department of General and Digestive Surgery Hospital Reina Sofía, Córdoba, Spain. Dr. Pedro Villarejo Campos, on behalf of Hospital Universitario Fundación Jiménez Díaz. Dr. Pedro Cascales Campos, on behalf of the Department of General and Digestive Surgery, Hospital Virgen de la Arrixaca, Murcia, Spain.

Author Contributions: Conceptualization, R.G.-S. and E.O.-M.; investigation, R.G.-S., E.O.-M., I.L.-U., A.L.-G., R.M.-H., J.M.-G., E.G.-M.N., F.M.-M., M.D.-A., M.A.O., M.Á.-M. and A.G.-C.; writing—original draft preparation, R.G.-S., E.O.-M., I.L.-U., A.L.-G., R.M.-H., J.M.-G., E.G.-M.N., F.M.-M., M.D.-A. and A.G.-C.; writing—review and editing, R.G.-S., E.O.-M., I.L.-U., A.L.-G., R.M.-H., J.M.-G., E.G.-M.N., F.M.-M., M.D.-A., M.A.O., M.Á.-M. and A.G.-C.; supervision; R.G.-S. and E.O.-M., project administration, M.A.O.; funding acquisition, M.Á.-M. and M.A.O. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by the Instituto de Salud Carlos III (Plan Estatal de I + D + I 2013–2016) and co-financed by the European Development Regional Fund “A way to achieve Europe” (ERDF) and B2017/BMD-3804 MITIC-CM, B2020/MITICAD-CM, HALEKULANY and MJR.

Institutional Review Board Statement: The study was carried out in accordance with the basic ethical principles of autonomy, beneficence, nonmaleficence and distributive justice, and its development followed the rules of Good Clinical Practice, the principles contained in the most recent Declaration of Helsinki (2013) and the Oviedo Convention (1997). The collected data and information complied with the current legislation on data protection (Organic Law 3/5 December 2018 on the Protection of Personal Data and the Guarantee of Digital Rights and Regulation (EU) 2016/679) approved by Hospital Universitario Príncipe de Asturias (0E17/2019).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data used to support the findings of the present study are available from the corresponding author upon request.

Conflicts of Interest: The authors declare no conflict of interest. Founding Role supported by COMBAT®. Role of the Funding Source: initial study of device regulatory approvals and external biostatistics analysis; the funders had no role in the design of the study; in the collection, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
21. Bushati, M.; Rovers, K.P.; Sommariva, A.; Sugarbaker, P.H.; Morris, D.L.; Yonemura, Y.; Quadros, C.A.; Somashkhar, S.P.; Ceelen, W.; Dube, P.; et al. The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI). Eur. J. Surg. Oncol. 2018, 44, 1942–1948. [CrossRef]

22. Glehen, O.; Cotte, E.; Kusamura, S.; Deraco, M.; Baratti, D.; Passot, G.; Beaujard, A.C.; Noel, G.F. Hyperthermic intraperitoneal chemotherapy: Nomenclature and modalities of perfusion. J. Surg. Oncol. 2008, 98, 242–246. [CrossRef] [PubMed]

23. Sánchez-García, S.; Padilla-Valverde, D.; Villarejo-Campos, P.; Martín-Fernández, J.; García-Rojo, M.; Rodriguez-Martínez, M. Experimental development of an intra-abdominal chemohyperthermia model using a closed abdomen technique and a PRS-1.0 Combat CO2 recirculation system. Surgery 2014, 155, 719–725. [CrossRef] [PubMed]

24. Soriano, R.M.; Cascales-Campos, P.A.; Gil Martínez, J. Cirugía de la Carcinomatosis Peritoneal, 1st ed.; Cirujanos, A.E.D., Ed.; ARÁN EDICIONES SL.: Madrid, Spain, 2018; Volume 6, p. 114.

25. Yonemura, Y.; Bandou, E.; Kawamura, T.; Endou, Y.; Sasaki, T. Quantitative prognostic indicators of peritoneal dissemination of gastric cancer. Eur. J. Surg. Oncol. 2006, 32, 602–606. [CrossRef] [PubMed]

26. Harmon, R.L.; Sugarbaker, P.H. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int. Semin. Surg. Oncol. 2005, 2, 3. [CrossRef]

27. Glehen, O.; Gilly, F.N. Quantitative prognostic indicators of peritoneal surface malignancy: Carcinomatosis, sarcomatosis, and peritoneal mesothelioma. Surg. Oncol. Clin. N. Am. 2003, 12, 649–671. [CrossRef]

28. Younan, R.; Kusamura, S.; Baratti, D.; Cloutier, A.S.; Deraco, M. Morbidity, toxicity, and mortality classification systems in the local regional treatment of peritoneal surface malignancy. J. Surg. Oncol. 2008, 98, 253–257. [CrossRef]

29. Sugarbaker, P.H.; Alderman, R.; Edwards, G.; Marquardt, C.E.; Gushchin, V.; Esquivel, J.; Chang, D. Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann. Surg. Oncol. 2006, 13, 635–644. [CrossRef]

30. Elias, D.; Gilly, F.; Boutitie, F.; Quenet, F.; Bereder, J.M.; Mansvelt, B.; Lorimier, G.; Dube, P.; Glehen, O. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: Retrospective analysis of 523 patients from a multicentric French study. J. Clin. Oncol. 2010, 28, 63–68. [CrossRef]

31. Glehen, O.; Osinsky, D.; Cotte, E.; Kwiatkowski, F.; Freyer, G.; Isaac, S.; Trillet-Lenoir, V.; Sayag-Beaujard, A.; François, Y.; Vignal, J. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: Morbidity and mortality analysis of 216 consecutive procedures. Ann. Surg. Oncol. 2003, 10, 863–869. [CrossRef]

32. Kusamura, S.; Younan, R.; Baratti, D.; Costanzo, P.; Favaro, M.; Gavazzi, C.; Deraco, M. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: Analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer 2006, 106, 1144–1153. [CrossRef] [PubMed]

33. Levine, E.A.; Stewart, J.H.T.; Russell, G.B.; Geisinger, K.R.; Loggie, B.L.; Shen, P. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: Experience with 501 procedures. J. Am. Coll. Surg. 2007, 204, 943–953; discussion 953–945. [CrossRef] [PubMed]

34. Sánchez-García, S.; Villarejo-Campos, P.; Padilla-Valverde, D.; Amo-Salas, M.; Martín-Fernández, J. Intraoperative chemotherapy hyperthermia (HIPEC) for peritoneal carcinomatosis of ovarian cancer origin by fluid and CO2 recirculation using the closed abdomen technique (PRS-1.0 Combat): A clinical pilot study. Int. J. Hyperth. 2016, 32, 488–495. [CrossRef]

35. Cianci, S.; Abatini, C.; Fagotti, A.; Chiofalo, B.; Tropea, A.; Biondi, A.; Scambia, G.; Pacelli, F. Hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancies in new hybrid CO2 system: Preliminary experience in referral center. Updat. Surg. 2019, 71, 555–560. [CrossRef] [PubMed]

36. Mehta, A.; Hoven, J.V.D.; Rosing, H.; Hillebrand, M.; Nuijen, B.; Huijtema, A.; Beijnen, J.; Verwaal, V. Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy. Int. J. Pharm. 2015, 479, 23–27. [CrossRef]

37. Pelz, J.O.; Stojadinovic, A.; Nissan, A.; Hohenberger, W.; Esquivel, J. Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis. J. Surg. Oncol. 2009, 99, 9–15. [CrossRef] [PubMed]

38. Glehen, O.; Gilly, F.N.; Arvieux, C.; Cotte, E.; Boutitie, F.; Mansvelt, B.; Bereder, J.M.; Lorimier, G.; Quenet, F.; Elias, D.; et al. Peritoneal carcinomatosis from gastric cancer: A multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann. Surg. Oncol. 2010, 17, 2370–2377. [CrossRef] [PubMed]

39. Yan, T.D.; Black, D.; Savady, R.; Sugarbaker, P.H. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J. Clin. Oncol. 2006, 24, 4011–4019. [CrossRef] [PubMed]

40. Quenet, F.; Elias, D.; Roca, L.; Goere, D.; Ghouti, L.; Pocard, M.; Facy, O.; Arvieux, C.; Lorimier, G.; Pefzet, D. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J. Clin. Oncol. 2018, 36, 3503. [CrossRef]

41. Beaujard, A.C.; Glehen, O.; Caillot, J.L.; Francois, Y.; Bienvenu, J.; Panteix, G.; Garbit, F.; Grandclement, E.; Vignal, J.; Gilly, F.N. Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. Cancer 2000, 88, 2512–2519. [CrossRef]
42. Quéné, F. Colorectal peritoneal carcinomatosis: What is the future of HIPEC? *Eur. J. Surg. Oncol.* 2018, 44, 1847–1848. [CrossRef] [PubMed]

43. Klaver, C.E.; Groenen, H.; Morton, D.G.; Laurberg, S.; Bemelman, W.A.; Tanis, P.J. The research committee of the European Society of Coloproctology Recommendations and consensus on the treatment of peritoneal metastases of colorectal origin: A systematic review of national and international guidelines. *Color. Dis.* 2017, 19, 224–236. [CrossRef] [PubMed]

44. Aoyagi, T.; Terracina, K.P.; Raza, A.; Takabe, K. Current treatment options for colon cancer peritoneal carcinomatosis. *World J. Gastroenterol.* 2014, 20, 12493–12500. [CrossRef]

45. Sanchez-Garcia, S.; Padilla-Valverde, D.; Villarejo-Campos, P.; Garcia-Santos, E.P.; Martin-Fernandez, J. Hyperthermic chemotherapy intra-abdominal laparoscopic approach: Development of a laparoscopic model using CO2 recirculation system and clinical translation in peritoneal carcinomatosis. *Int. J. Hyperth.* 2017, 33, 684–689. [CrossRef] [PubMed]

46. Van der Speeten, K.; Stuart, O.A.; Sugarbaker, P.H. Pharmacokinetics and pharmacodynamics of perioperative cancer chemotherapy in peritoneal surface malignancy. *Cancer J.* 2009, 15, 216–224. [CrossRef] [PubMed]

47. Sugarbaker, P. Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. *Int. J. Hyperth.* 2007, 23, 431–442. [CrossRef]

48. Armour, E.P.; McEachern, D.; Wang, Z.; Corry, P.M.; Martinez, A. Sensitivity of human cells to mild hyperthermia. *Cancer Res.* 1993, 53, 2740–2744. [PubMed]

49. Issels, R.D. Hyperthermia adds to chemotherapy. *Eur. J. Cancer* 2008, 44, 2546–2554. [CrossRef]

50. Pelz, J.O.; Vetterlein, M.; Grimmig, T.; Kerscher, A.G.; Moll, E.; Lazariotou, M.; Matthes, N.; Faber, M.; Germer, C.T.; Waaga-Gasser, A.M.; et al. Hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis: Role of heat shock proteins and dissecting effects of hyperthermia. *Ann. Surg. Oncol.* 2013, 20, 1105–1113. [CrossRef] [PubMed]

51. Kusamura, S.; Dominique, E.; Baratti, D.; Younan, R.; Deraco, M. Drugs, carrier solutions and temperature in hyperthermic intra- peritoneal chemotherapy. *J. Surg. Oncol.* 2008, 98, 247–252. [CrossRef] [PubMed]

52. Yonemura, Y.; de Aretxabala, X.; Fujimura, T.; Fushida, S.; Katayama, K.; Bandou, E.; Sugiyama, K.; Kawamura, T.; Kinoshita, K.; Endou, Y.; et al. Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: Final results of a randomized controlled study. *Hepatogastroenterology* 2001, 48, 1776–1782. [PubMed]

53. Esquis, P.; Consolo, D.; Magnin, G.; Pointaire, P.; Moreto, P.; Ynsa, M.D.; Beltram, J.L.; Drogoul, C.; Simonet, M.; Benoit, L.; et al. High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis. *Ann. Surg.* 2006, 244, 106–112. [CrossRef] [PubMed]

54. Elias, D.; Benizri, E.; Di Pietrantonio, D.; Menegon, P.; Malka, D.; Raynard, B. Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis. *Ann. Surg. Oncol.* 2007, 14, 509–514. [CrossRef] [PubMed]